The UAE became the first country globally to approve Rinvok for treating non-segmental vitiligo in patients over 12. This move highlights the country's rapid adoption of advanced medical treatments.
Our retelling · details in the original publication
The Emirates Drug Authority has officially approved the use of a new drug named Rinvok for local patients. This medication is intended for the treatment of non-segmental vitiligo. It is suitable for individuals who are aged 12 and older. With this decision, the UAE becomes the first country in the world to adopt the expanded use of this specific pharmaceutical product.
Vitiligo is a medical condition that results in the loss of skin colour in patches. It happens when the skin loses its pigment cells, often creating noticeable discolored areas on different parts of the body. Currently, there is no absolute cure for this disorder, which affects between 0.5 and 1 per cent of the global population.
This approval highlights the advanced position of the UAE in healthcare. It shows a commitment to keeping pace with the latest pharmaceutical innovations. Residents affected by vitiligo now have access to a new treatment option much sooner than in other regions. You should consult a doctor to see if this treatment is suitable for your case. Full details are available in the original publication.
Want to know how this affects you?
Ask the ecosystem on Telegram — I'll personally shortlist 2–3 properties that benefit from this change.
